ALBIGER, NORA MARIA ELVIRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.372
EU - Europa 349
AS - Asia 290
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 4.015
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.367
CN - Cina 210
SE - Svezia 65
VN - Vietnam 64
IT - Italia 63
FI - Finlandia 61
DE - Germania 51
GB - Regno Unito 49
UA - Ucraina 39
IE - Irlanda 8
IN - India 8
BZ - Belize 5
NL - Olanda 4
PL - Polonia 4
FR - Francia 3
JP - Giappone 3
TR - Turchia 2
AM - Armenia 1
AU - Australia 1
BE - Belgio 1
CO - Colombia 1
EU - Europa 1
HK - Hong Kong 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
Totale 4.015
Salva come PNG Salva come JPEG
Città #
Fairfield 571
Woodbridge 347
Chandler 334
Ann Arbor 322
Houston 251
Ashburn 243
Seattle 210
Cambridge 207
Wilmington 186
Jacksonville 168
Beijing 80
Princeton 68
Dong Ket 64
San Diego 50
Des Moines 38
Medford 28
Padova 28
Helsinki 26
Nanjing 26
Boardman 24
Roxbury 20
Nanchang 10
Dublin 8
Jiaxing 7
London 7
Shenyang 7
Falls Church 6
Florence 6
Jinan 6
New York 6
Redwood City 6
Zhengzhou 6
Belize City 5
Hebei 5
Hefei 5
Los Angeles 5
Renton 5
San Jose 5
Tianjin 5
Borås 4
Columbus 4
Indiana 4
Kunming 4
Norwalk 4
Changsha 3
Dearborn 3
Kharkiv 3
Ogden 3
Shanghai 3
Washington 3
Albuquerque 2
Auburn Hills 2
Fuzhou 2
Istanbul 2
Lanzhou 2
Las Vegas 2
Milan 2
Nürnberg 2
Paris 2
Piove Di Sacco 2
Rockville 2
Rome 2
Vicenza 2
Wroclaw 2
Acton 1
Atlanta 1
Augusta 1
Buffalo 1
Böblingen 1
Canberra 1
Carmignano Di Brenta 1
Catania 1
Charlotte 1
Chicago 1
Chiswick 1
Chongqing 1
Christchurch 1
Groningen 1
Guangzhou 1
Haikou 1
Hangzhou 1
Hounslow 1
Islington 1
Kiev 1
Kilburn 1
Latsch 1
Leawood 1
Liège 1
Magdeburg 1
Medellín 1
Miami 1
New Bedfont 1
Ningbo 1
Oslo 1
Pune 1
Rodgau 1
Saint Louis 1
San Francisco 1
Simi Valley 1
Southwark 1
Totale 3.503
Salva come PNG Salva come JPEG
Nome #
Paradoxical GH increase during OGTT is associated to first-generation somatostatin analogs responsiveness in acromegaly 154
Diagnosis and complications of Cushing's disease: gender-related differences. 147
Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor 133
AHR over-expression in papillary thyroid carcinoma: clinical and molecular assessments in a series of Italian acromegalic patients with a long-term follow-up 125
The Role of Unilateral Adrenalectomy in ACTH-Independent Macronodular Adrenal Hyperplasia (AIMAH). 124
An analysis of different therapeutic options in patients with Cushing's syndrome due to bilateral macronodular adrenal hyperplasia: A single-centre experience 120
A case of primary aldosteronism in pregnancy: do LH and GNRH receptors have a potential role in regulating aldosterone secretion? 118
Screening tests for cushing's syndrome: Urinary free cortisol role measured by LC-MS/MS 116
Adrenal lesions in acromegaly: do metabolic aspects and aryl hydrocarbon receptor interacting protein gene have a role? Evaluation at baseline and after long-term follow-up. 115
Early recognition of aggressive pituitary adenomas: a single-centre experience 113
Idiopathic primary hyperaldosteronism: normalization of plasma aldosterone after one month withdrawal of long-term therapy with aldosterone-receptor antagonist potassium canrenoate 108
Combination therapy for Cushing's disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole? 108
Metyrapone treatment in Cushing’s syndrome: a real-life study 108
Long-term glucocorticoid effect on bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency 100
Thrombin generation in Cushing's Syndrome: do the conventional clotting indices tell the whole truth? 99
Adrenal nodules in patients with Cushing's disease: prevalence, clinical significance and follow-up. 99
Decrease in salivary cortisol levels after glucocorticoid dose reduction in patients with adrenal insufficiency: A prospective proof-of-concept study 98
A multicenter experience on the prevalence of ARMC5 mutations in patients with primary bilateral macronodular adrenal hyperplasia: from genetic characterization to clinical phenotype 97
Second-line tests in the differential diagnosis of ACTH-dependent Cushing’s syndrome 97
Different therapeutic options in patients with Cushing's syndrome due to bilateral macronodular adrenal hyperplasia 95
Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study 94
Daily salivary cortisol and cortisone rhythm in patients with adrenal incidentaloma 94
The R304X mutation of the Aryl hydrocarbon receptor Interacting Protein gene in familial isolated pituitary adenomas: mutational Hot-Spot or founder effect? 89
Hypercortisolism and pregnancy upregulate von Willebrand factor through different mechanisms: report on a pregnant patient with Cushing's syndrome. 89
Therapeutic strategies for Cushing's syndrome: An update 88
The glucose-dependent insulinotropic polypeptide receptor (GIPR) is overexpressed amongst GNAS1 mutation-negative somatotropinomas and drives GH-promoter activity in GH3 cells. 87
Predicting late recurrence in surgically-treated patients with Cushing's disease. 84
The usefulness of combined biochemical tests in the diagnosis of Cushing's disease with negative pituitary magnetic resonance imaging 83
Venous thromboembolism in patients with Cushing's syndrome: need of a careful investigation of the prothrombotic risk profile. 82
Cardiovascular autonomic dysfunction in patients with idiopathic diabetes insipidus 81
Allelic Variants of ARMC5 in Patients With Adrenal Incidentalomas and in Patients With Cushing's Syndrome Associated With Bilateral Adrenal Nodules 79
Effect of short term therapy with recombinant human growth hormone (GH) on metabolic parameters and preclinical atherosclerosis markers in hypopituitary patients with growth hormone deficiency. 77
Patients with Cushing's syndrome have increased intimal media thickness at different vascular levels: comparison with a population matched for similar cardiovascular risk factors. 77
Adrenal morpho-functional alterations in patients with acromegaly. 77
Microsatellite (GT)(n) is part of the von Willebrand factor (VWF) promoter region that influences the glucocorticoid-induced increase in VWF in Cushing's syndrome. 75
The GIP/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of gsp(-) somatotropinomas 75
Assessment of glucocorticoid therapy with salivary cortisol in secondary adrenal insufficiency. 65
Cyclic Cushing's syndrome: an overview. 61
Haplotypes of Von Willebrand factor promoter predict thrombotic risk in Cushing's syndrome 59
Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease. 56
Aterosclerosi extra coronaria nella sindrome di Cushing 53
Peroxisome proliferator-activated receptor gamma in the human pituitary gland: expression and splicing pattern in adenomas versus normal pituitary. 51
Utilità  dell'uso dei test (DDAVP, CRH e 8 MG DEX OVERNIGHT) nell'indicazione chirurgica e nell'outcome della malattia di Cushing 47
Sindrome di Cushing e rischio cardiovascolare 45
The role of the size in thyroid cancer risk stratification 45
Corticotropin-releasing hormone test predicts the outcome of unilateral adrenalectomy in primary bilateral macronodular adrenal hyperplasia 3
Totale 4.090
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.589
article - articoli 13.212
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.801
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019276 0 0 0 0 0 0 0 0 0 0 149 127
2019/2020995 106 40 17 112 98 70 101 109 110 101 77 54
2020/2021612 37 51 30 53 15 27 13 50 79 93 66 98
2021/2022685 14 73 82 52 63 48 18 87 28 15 63 142
2022/2023583 125 89 6 89 78 71 1 36 54 3 26 5
2023/2024212 5 39 33 14 31 30 36 12 5 7 0 0
Totale 4.090